12 NEWS
Bicosome acquires biomimetic lipid gel skincare platform patents
Bicosome has acquired two patents for biomimetic lipid gel skincare platforms developed at the Institute of Advanced Chemistry of Catalonia (IQAC) from the Spanish National Research Council (CSIC). The new technological
platforms do not need the presence of polymers, surfactants, or other gelling agents, bringing valuable benefits for skin care, especially sensitive skin. “The structure and fluidity of
the biomimetic gels respond in a reversible way to temperature and pH and their rheological behaviour makes them easy to apply topically. They will be able to be used at a surface level as a cutaneous acid mantle
substitute, protecting the skin as well as acting as a reservoir for target molecules,” said Bicosome technical director Gelen Rodriguez. The collaboration between
Bicosome and IQAC is long term and focused on generating natural, sustainable, and environmentally friendly solutions for skin care. Their first collaboration gave
rise to the Bicosome dual delivery systems patent, a nanostructured technology that mimics the lamellar bodies transportation function into target skin layers. This patent generated most products within the current Bicosome portfolio. The new lipid gel patents are complementary to Biosome’s
current IP for skin delivery. Olga Lopez, the leader of the
invention and scientist at IQAC – CSIC, said: “The biomimetic gels have a unique organization, with part of the water being trapped in a framework of lipid structures. This makes them ample to transport actives of a different nature due to the actives being in
different compartments.” The gels exclusive hydrolipidic
composition guarantees a high biocompatibility and its capacity to respond to biological parameters points to promising applications in future products. Bicosome CEO Lucyanna
Barros added: “These new technologies are perfectly in line with the company’s mission to create innovative technologies mimicking skin functions in order to provide customers with sophisticated nature driven skin delivery solutions.” The Barcelona company
estimates the first products with the new technology will be fully available for customers within two years.
Solabia snaps up Dutch active ingredient maker BioActor
Solabia has acquired BioActor, a Dutch developer of natural active ingredients used by food supplement brands. The French outfit said the
investment will allow Solabia to benefit from a wider range of ingredients and from BioActor’s expertise as customers increasingly look for high quality actives that combine naturality with proof of efficacy. Founded in 2011 and located
on the Maastricht Health Campus, BioActor develops and commercialises clinically evaluated polyphenols extracted from edible plants and fruits.
BioActor currently exports
to more than 20 countries worldwide, serving leading brands across the nutrition and supplement industries. Solabia said the acquisition will also support BioActor’s continued focus on R&D and product development, as well as the expansion of its production capabilities, enabling the company to serve the increasing global demand for its products. The Paris company is already
present in the nutrition segment through original ingredients recognized for their health benefits, including Algatech’s
combined network and expertise, as well as to access new marketing channels and an expanded customer base,” a spokeswoman said. Hans van der Saag, BioActor’s
founder, retains a minority share and his role as CEO of BioActor. “Together with Solabia,
microalgae-derived active ingredients. “BioActor will become a centre
of excellence for innovation and clinical research within Solabia’s nutrition division and the combination will allow both companies to benefit from the
we are poised to extend the BioActor growth story as part of a larger organisation with an extensive global footprint, a shared commitment to innovation, research and development, and an unwavering focus on utilising the benefits of nutrition to elevate the health of all of us,” he said.
Univar Solutions buys Turkish distributor Kale Kimya
US speciality chemicals distributor Univar Solutions is to acquire Turkish counterpart Kale Kimya. Established in 1975, the Istanbul
outfit has formulation lab capabilities plus an extensive product portfolio of beauty products. These include surfactants,
actives, emulsifiers, preservatives, UV filters, fragrances, polymers, conditioners, esters and emollients. Terms of the transaction were not disclosed. Closing of the
PERSONAL CARE March 2023
acquisition is subject to certain regulatory approvals and is expected to be completed within Q1 2023. “This acquisition further
progresses our strategy to grow our Ingredients and Specialties business
with a leading company that builds on and adds to our strengths, geographic footprint and product portfolio,” said Nick Powell, Univar president of Global Ingredients & Specialties.
“I am delighted to soon
welcome Kale Kimya to the Univar Solutions family. Their experience and knowledge will support our customers in the region, as we continue to capitalize on changing consumer trends,” he added.
Kale Kimya CEO Birgen Kaleağası
Özemre said: “This acquisition is a great fit between two companies that share market-leading reputations, expert technical support, a spirit of innovation and relentless dedication to exceptional customer service. “This will support the growth
of our people and products even further, and I look forward to becoming a unified company with Univar Solutions.”
www.personalcaremagazine.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103
